GENI (GENI) Stock Price & Analysis
GENI (GENI) rose 4.64% to USD 6.76 as of June 9, 2026 at 23:54 UTC, according to Nexqual real-time market data.
GENI last closed at USD 6.46; the session ranged USD 6.38–7.11 on volume of 8,523,499 shares. Market capitalization is $1.81B, with a 52-week range of USD 3.83–13.73 (NYQ). Source: Nexqual, June 9, 2026 at 23:54 UTC.
Key Statistics (as of June 9, 2026 at 23:54 UTC)
| Price | USD 6.76 |
|---|---|
| Change | ▲ 4.64% (up) |
| Previous Close | USD 6.46 |
| Open | USD 6.4 |
| Day Range | USD 6.38 – 7.11 |
| 52-Week Range | USD 3.83 – 13.73 |
| Volume | 8,523,499 shares |
| Market Cap | $1.81B |
| Exchange | NYQ |
Technical Analysis (GENI)
Nexqual's technical model rates GENI "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:54 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 71.33 (overbought) |
| vs SMA50 | Above (USD 4.83) |
| MACD | 0.48 (positive) |
Analyst Ratings (GENI)
Wall Street analysts rate GENI "Strong Buy" based on 18 analysts, with a mean price target of USD 10.19 (range USD 5–19), per Nexqual as of June 9, 2026 at 23:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 10.19 |
| High Target | USD 19 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 16 / 2 / 0 |
Earnings (GENI)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $184.83M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.02 vs est 0.01 ▲ beat |
| 2025-12-31 | USD -0.02 vs est 0.13 ▼ miss |
| 2025-09-30 | USD -0.04 vs est 0.07 ▼ miss |
| 2025-06-30 | USD -0.27 vs est -0.05 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:54 UTC.
Financials & Fundamentals (GENI)
| Total Revenue | $713.45M |
|---|---|
| Revenue Growth (YoY) | +30.50% |
| Gross Margin | +22.70% |
| Operating Margin | -15.76% |
| Profit Margin | -22.26% |
| ROE | -22.60% |
| Debt / Equity | 4.4 |
| Current Ratio | 1.6 |
| Total Cash | $197.44M |
| Total Debt | $30.55M |
| Free Cash Flow | $100.55M |
Source: Nexqual, June 9, 2026 at 23:54 UTC.
Financial Health Score (GENI)
Nexqual rates GENI's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:54 UTC.
| Growth | Strong — Revenue +31% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 23%, operating -16% |
| Balance Sheet | Strong — $197M cash vs $31M debt, net cash position |
| Cash Flow | Strong — FCF $101M, 15% margin |
| Efficiency | Critical — ROE -23%, ROA -10.0% |
Ownership (GENI)
| Insider Ownership | +9.43% |
|---|---|
| Institutional Ownership | +90.85% |
| Shares Outstanding | 267.34M |
| Float | 207.72M |
| Short % of Float | +9.10% |
Source: Nexqual, June 9, 2026 at 23:54 UTC.
Leadership (GENI)
GENI is led by Mark Adrian Locke (age 46), Co-Founder & CEO, per Nexqual as of June 9, 2026 at 23:54 UTC.
| Co-Founder & CEO | Mark Adrian Locke (age 46) |
|---|---|
| CFO & Director | Bryan David Castellani (age 54) |
| Chief Product & Technology Officer | Matt Fleckenstein |
| Chief Marketing Officer | Tony Marlow |
| Chief Commercial Officer & Director | Jack Alexander Davison (age 49) |
Major Backers & Investors (GENI)
Notable institutional backers of GENI include Senvest Management LLC, Voss Capital, LP, Shapiro Capital Management LLC, according to Nexqual as of June 9, 2026 at 23:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Senvest Management LLC | 5.54% |
| Voss Capital, LP | 5.31% |
| Shapiro Capital Management LLC | 4.31% |
| Glenview Capital Management, Llc | 3.48% |
| Stephens Investment Management Group LLC | 3.08% |
| Discovery Capital Management, LLC | 3.03% |
| Hood River Capital Management LLC | 2.94% |
| Times Square Capital Management, LLC | 2.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.03% |
Source: Nexqual, June 9, 2026 at 23:54 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRAD | Sportradar Group AG | USD 16.4 | ▲ 17.99% |
| RSI | Rush Street Interactive, Inc. | USD 27.59 | ▲ 5.55% |
| SRTA | Strata Critical Medical, Inc. | USD 5.61 | ▼ 3.11% |
| PSFE | Paysafe Limited | USD 7.04 | ▲ 2.03% |
| MQ | Marqeta, Inc. | USD 3.97 | ▲ 2.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:54 UTC. This page is informational and not investment advice.